Colorectal Cancer (CRC) Recruiting Phase 3 Trials for Fluorouracil (DB00544)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

IndicationStatusPhase
DBCOND0031867 (Colorectal Cancer (CRC))Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT07676162
A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal CancerTreatment
NCT07775287
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)Treatment
NCT06783491
Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon CancerTreatment
NCT05768503
Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRCTreatment
NCT07412613
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon CancerTreatment
NCT06794086
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver MetastasesTreatment
NCT06520683
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal CancerTreatment
NCT06501482
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRITreatment
NCT06275958
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal CancerTreatment
NCT05008809
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)Treatment
NCT04861558
Efficacy of Hyperthermic Intraperitoneal ChemotherapyTreatment
NCT04687631
Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver MetastasesTreatment
NCT04516681
Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal CancerTreatment
NCT05797077
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNATreatment
NCT05861505
COLLISION RELAPSE TrialTreatment
NCT05815082
ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal CancerTreatment
NCT05797467
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer PatientsTreatment
NCT03925662
Mebendazole as Adjuvant Treatment for Colon CancerTreatment
NCT06791512
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRCTreatment
NCT06733038
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.Treatment
NCT07284849
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerTreatment